These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Dendritic Cells Cause Bone Lesions in a New Mouse Model of Histiocytosis. Grosjean F; Nasi S; Schneider P; Chobaz V; Liu A; Mordasini V; Moullec K; Vezzoni P; Lavanchy C; Busso N; Acha-Orbea H; Ehirchiou D PLoS One; 2015; 10(8):e0133917. PubMed ID: 26247358 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071 [TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Smith MR Cancer Treat Rev; 2005; 31 Suppl 3():19-25. PubMed ID: 16229955 [TBL] [Abstract][Full Text] [Related]
11. Langerhans cell histiocytosis of long bones: MR imaging and complete follow up study. Hashmi MA; Haque N; Chatterjee A; Guha S J Cancer Res Ther; 2012; 8(2):286-8. PubMed ID: 22842377 [TBL] [Abstract][Full Text] [Related]
12. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of zoledronic acid in Erdheim-Chester disease: A case report. Poiroux L; Paycha F; Polivka M; Ea HK Joint Bone Spine; 2016 Oct; 83(5):573-5. PubMed ID: 26987264 [TBL] [Abstract][Full Text] [Related]
15. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Lein M; Miller K; Wirth M; Weissbach L; May C; Schmidt K; Haus U; Schrader M; Jung K Prostate; 2009 May; 69(6):624-32. PubMed ID: 19143027 [TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate therapy for unresectable symptomatic benign bone tumors: a long-term prospective study of tolerance and efficacy. Cornelis F; Truchetet ME; Amoretti N; Verdier D; Fournier C; Pillet O; Gille O; Hauger O Bone; 2014 Jan; 58():11-6. PubMed ID: 24120668 [TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid palliation in bone-metastatic breast cancer. Furlow B Lancet Oncol; 2006 Nov; 7(11):894. PubMed ID: 17099983 [No Abstract] [Full Text] [Related]
18. The use of zoledronic acid for Paget's disease of bone. Maricic M Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007 [TBL] [Abstract][Full Text] [Related]
19. Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study. Khalafallah AA; Slancar M; Cosolo W; Abdi E; Chern B; Woodfield RJ; Copeman MC Eur J Cancer Care (Engl); 2018 Mar; 27(2):e12638. PubMed ID: 28134499 [TBL] [Abstract][Full Text] [Related]
20. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA; Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]